Genetic testing company Agendia and artificial intelligence (AI) pathology company Paige have partnered to improve planning for breast cancer treatment, with the goal of enabling faster access to genetic information for women.
The partnership enables Agendia and Paige to develop treatment planning tools that integrate the cloud-based Paige platform using genomic information from Agendia's MammaPrint and BluePrint diagnostic tests for breast cancer patients.
The goal of the partnership is to enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning, according to the companies.
